NEW YORK (Reuters) -More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Investing.com -- Denmark’s export and investment fund EIFO and the Novo Nordisk (NYSE: NVO) Foundation are investing €80 ...

Denmark is launching a quantum project as it makes a bold step to lead global race in quantum computing backed by Novo Nordisk Foundation.

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...

Denmark launches QuNorth, an €80M initiative to build the 'Magne' quantum computer. Backed by Microsoft, it aims for quantum ...